At Excipio Technologies, we can offer you solutions to address an unmet need in faster, more specific and efficient exosome isolation for the development of molecular diagnostics and therapeutic technologies.
The company was formed from a partnership between the Atlantic Cancer Research Institute, a non-profit organization located in Moncton (NB, Canada), and New England Peptide, a Boston (MA, United States) based biotech manufacturer, in order to commercialize the Vn96 peptide and create positive business collaborations.
Our growing team of experts provides product launch and commercialization support for the Vn96 extracellular vesicle isolation technology. We are also committed to the discovery of new applications for the Vn96 technology.
What we can do for you
We can help you increase the accessibility to more efficient, reliable and faster diagnostics directly on site or at the point of care. Our proprietary technology can increase the specificity and sensitivity of your biofluid-based molecular diagnostic assays by enriching biomarkers of interest. The Vn96 peptide technology is an efficient and specific extraction method for extracellular vesicles derived from stressed cells using your existing infrastructure, minimizing your isolation time to less than an hour and eliminating the need for ultracentrifugation or expensive antibodies and filtration methods.
Excipio Technologies will assist you in the development of better diagnostics, detection therapeutics and treatments for human and animal health with the integration of our patented Vn96 technology.